You are here: Industry Insights > Kineta

News List

Samsung Biologics, Kineta Enter Development and Manufacturing Agreement contractpharma
July 21, 2021
Samsung's San Francisco R&D center and South Korea headquarters to offer end-to-end CDMO service for anti-VISTA antibody immunotherapy.
Kineta Announces First Participant Dosed in KCP506 Trial for Chronic Pain americanpharmaceuticalreview
December 17, 2020
Kineta, through its subsidiary Kineta Chronic Pain LLC, announced the first participant has been successfully dosed in a Phase 1 clinical trial of KCP506, an investigational, first-in-class α9/α10 nicotinic acetylcholine receptor (nAChR) antagonist in ...
Kineta Receives Regulatory Approval for Initiation of KCP506 Trial americanpharmaceuticalreview
August 18, 2020
Kineta announced the Clinical Trial Application (CTA) approval in the Netherlands for initiation of a first in-human clinical trial of KCP506. KCP506 is a first-in-class α9α10 nicotinic acetylcholine receptor (nAChR) antagonist in development for the ...
Kineta Enters Research Collaboration and License Agreement with Pfizer americanpharmaceuticalreview
December 18, 2018
Kineta Immuno-Oncology has entered into a strategic research collaboration with Pfizer to develop RIG-I agonist immunotherapies for the treatment of cancer.....
Kineta Chronic Pain Inks License Deal with Genentech for Over $359 Million biospace
April 18, 2018
Seattle-based Kineta Chronic Pain, a subsidiary of Kineta, signed an exclusive option and license deal with Genentech, a Roche company.
Kineta to Collaborate on the Development of a Novel Non-Opioid Pain Therapy with Genentech biospace
April 17, 2018
Kineta today announced that it has entered into an exclusive option and license agreement with Genentech, Inc., a member of the Roche Group, to develop Kineta's α9/α10 nicotinic acetylcholine receptor (nAChR) antagonists for the treatment of chronic pain.